March 22, 2019acro

thumbnail
We're Not Sweatshops

ACRO Responds to NEJM

January 02, 2008

The recent New England Journal of Medicine (NEJM) article that criticized contract research organizations (CROs) was a roundhouse kick to the gut of that industry. The Oct. 4, 2007 article, written by New York psychiatrist and professor Miriam Shuchman, asserted that as CROs have expanded from $7 billion in revenues in 2001 to $17.8 billion today, science has suffered. Ignoring thousands of trials that unfold without a hitch, Shuchman cites several headline-grabbing studies-gone-awry that involved CROs. (Think TeGenero.) Shuchman believes that the industry has no clear regulatory oversight, leaving the door open for unethical behavior on the part of CROs and the sponsors who hire them. The commercialization of clinical trials, writes Shuchman, is a matter of ever-growing societal importance as CROs take over more of Phase I, II and III research—64 percent of it in 2003, compared to just 28 percent 10 years earlier. ACRO Stunned The CRO industry’s top…more...

No articles available

No articles available

No articles available


© 2019 ClinPage. All Rights Reserved.